Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Postoperative Complications
Description
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. MeSH
Hierarchy View
Subtype Terms (27)
Anastomotic Leak
18 drugs (14 approved, 4 experimental)
Breast Cancer Lymphedema
3 drugs (2 approved, 1 experimental)
Corneal Endothelial Cell Loss
12 drugs (6 approved, 6 experimental)
Coronary-Subclavian Steal Syndrome
Delayed Emergence from Anesthesia
24 drugs (23 approved, 1 experimental)
Emergence Delirium
27 drugs (23 approved, 4 experimental)
Failed Back Surgery Syndrome
4 drugs (3 approved, 1 experimental)
Graft Occlusion, Vascular
3 experimental drugs
Incisional Hernia
2 drugs (1 approved, 1 experimental)
Malignant Hyperthermia
1 approved drug
Pain, Postoperative
209 drugs (135 approved, 74 experimental)
Postcholecystectomy Syndrome
1 experimental drug
Postoperative Cognitive Complications
28 drugs (25 approved, 3 experimental)
Postoperative Hemorrhage
22 drugs (16 approved, 6 experimental)
Postoperative Nausea and Vomiting
105 drugs (83 approved, 22 experimental)
Postpericardiotomy Syndrome
1 approved drug
Prosthesis Failure
7 drugs (6 approved, 1 experimental)
Prosthesis-Related Infections
27 drugs (22 approved, 5 experimental)
Reperfusion Injury
80 drugs (60 approved, 20 experimental)
Shock, Surgical
1 approved drug
Short Bowel Syndrome
38 drugs (20 approved, 18 experimental)
Surgical Wound Dehiscence
1 approved drug
Surgical Wound Infection
58 drugs (44 approved, 14 experimental)
Vasoplegia
12 drugs (11 approved, 1 experimental)
Approved Indicated Drugs (2)
Phase 3 Indicated Drugs (31)
Phase 2 Indicated Drugs (21)
Other Experimental Indicated Drugs (43)
Organization Involved with Phase 4 Indications (59)
Aristotle University of Thessaloniki
China Food and Drug Administration
Chinese Academy of Medical Sciences
Hospital General Universitario Gregorio Marañon
Huazhong University of Science and Technology
Institute of Liver and Biliary Sciences, India
Organization Involved with Phase 2 Indications (11)
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (56)
Hospital Fundación de Alcorcon
Hospital general Universitario de Ciudad Real
Hospital Son Espases, Palma Mallorca
Hospital Universitario Central de Asturias
Medical University of South Carolina
Multicenter Clinical Study Group of Osaka
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Odontologisk Forskning i Region Skåne (OFRS)
Saint-Pierre University Hospital
Second Military Medical University
State University of New York, Buffalo
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
